Literature DB >> 26319313

Species and mediator specific TLR4 antagonism in primary human and murine immune cells by βGlcN(1↔1)αGlc based lipid A mimetics.

Chiranjeevi Chebrolu1, Daniel Artner2, Anna M Sigmund1, Jan Buer1, Alla Zamyatina2, Carsten J Kirschning3.   

Abstract

Immune stimulatory pathogen associated molecular patterns (PAMPs) are major drivers of infection pathology. Infections with Gram-negative bacteria or negatively polar and single stranded RNA influenza virus are prominent causes of morbidity and mortality. Toll-like receptor (TLR) 4 is a major host sensor for both of the two infections. In order to inhibit TLR4 driven immune activation we recently developed synthetic tetra-acylated lipid A mimetics based on a conformationally restricted βGlcN(1↔1)αGlcN disaccharide scaffold (DA-compounds) that antagonized ectopically overexpressed human and murine TLR4/MD-2 complexes. Here we comparatively analyzed human peripheral blood mononuclear cell (hPBMC) and murine bone marrow derived macrophage (mBM) activation upon 30 min of preincubation in vitro with six variably acylated DA-compounds. 16 h subsequent to consequent LPS challenge, we sampled culture supernatants for cytokine and NO concentration analysis. Four compounds significantly inhibited release of both TNF and IL-6 by hPBMCs upon LPS challenge. In contrast, three compounds effectively inhibited mBM production of MIP-2 and KC, and even five of them inhibited IL-6 and NO production. LPS driven like other TLR ligand driven mBM TNF release was largely unimpaired. The inhibitory effect was specific in that Clo75 driven cytokine release by both hPBMCs and mBMs was unimpaired by the compounds analyzed. Our results indicate biological species specificity of LPS antagonism by variably tetraacylated lipid A mimetics and validate three out of six DA-antagonists as promising candidates for development of therapeutically applicable anti-inflammatory compounds.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD14; LPS; MD-2; PRRs; TLR4; Therapeutic blockade

Mesh:

Substances:

Year:  2015        PMID: 26319313     DOI: 10.1016/j.molimm.2015.07.037

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  3 in total

1.  UVliPiD: A UVPD-Based Hierarchical Approach for De Novo Characterization of Lipid A Structures.

Authors:  Lindsay J Morrison; W Ryan Parker; Dustin D Holden; Jeremy C Henderson; Joseph M Boll; M Stephen Trent; Jennifer S Brodbelt
Journal:  Anal Chem       Date:  2016-01-15       Impact factor: 6.986

Review 2.  The relationship between toll like receptor 4 gene rs4986790 and rs4986791 polymorphisms and sepsis susceptibility: A meta-analysis.

Authors:  Rui Liu; Yuan-Yuan Mo; Hui-Li Wang; Yan Tan; Xiu-Jie Wen; Man-Jing Deng; Hong Yan; Lei Li
Journal:  Sci Rep       Date:  2016-12-13       Impact factor: 4.379

3.  Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics.

Authors:  Holger Heine; Florian Adanitsch; Tina Tinkara Peternelj; Mira Haegman; Christoph Kasper; Simon Ittig; Rudi Beyaert; Roman Jerala; Alla Zamyatina
Journal:  Front Immunol       Date:  2021-03-18       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.